advertisement The need-to-know this morning BiogenandEisai‘s FDA application for a subcutaneous version of the Alzheimer’s drug Leqembi has been delayed. The FDA has asked for three months of immunogenicity data and a Fast Track designation-specific application. A genetic clue to suppressin...